Health ❯ Clinical Trials ❯ Phase 1 Trials ❯ Vaccine Development

RSV Vaccines

Sanofi Signs $1.15 Billion Deal to Acquire Vicebio’s Molecular Clamp Respiratory Vaccine Platform

The agreement bolsters Sanofi’s non-mRNA vaccine portfolio by adding combination candidates that use a protein-stabilization platform ahead of a Q4 2025 closing.